AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca koselugo (selumetinib) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, Q2 2026
177
Period ended Jun 30, 2026
Change on a year earlier
+29.2%
137 in Q2 2025
History
25 quarters
Since Q2 2020
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up koselugo (selumetinib) — worldwide product sales ($m)
- Koselugo (selumetinib) — Worldwide YoY actual (%)29.0% · Q2 2026
- Koselugo (selumetinib) — Worldwide YoY CER (%)27.0% · Q2 2026
- Koselugo (selumetinib) — US product sales ($M)52 · Q2 2026
- Koselugo (selumetinib) — Emerging Markets product sales ($M)54 · Q2 2026
- Koselugo (selumetinib) — Europe product sales ($M)50 · Q2 2026
- Koselugo (selumetinib) — Established RoW product sales ($M)21 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Koselugo (selumetinib) — Worldwide product sales ($M) ($M), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_koselugo_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.